Related Experiment Videos
[Drug therapy for corneo-conjunctival neoplasm]
A Murcia López1, J Borrás Blasco, M C Alvarado Valero
1Servicio de Oftalmología, Hospital General Universitario de Elche, Alicante, Spain.
Summary
Interferon alpha 2b is a promising adjuvant therapy for corneo-conjunctival neoplasm, showing a 100% response rate and low adverse effects. Mitomycin C is effective but causes more side effects, while 5-fluorouracil is a less preferred option.
Area of Science:
- Ophthalmology
- Oncology
- Pharmacology
Context:
- Corneo-conjunctival neoplasms require effective adjuvant therapies to reduce high relapse rates post-resection.
- Topical chemotherapies like mitomycin C, 5-fluorouracil, and interferon alpha 2b have been explored for adjuvant treatment.
Purpose:
- To review and compare the clinical effectiveness of various topical drug therapies used as adjuvants for corneo-conjunctival neoplasm.
Summary:
- A literature search (1966-2004) identified studies on 5-fluorouracil, mitomycin C, and interferon alpha 2b for ocular neoplasms.
- Interferon alpha 2b demonstrated a 100% response rate with minimal adverse effects and a 4% relapse rate.
- Mitomycin C showed a 90% response rate but with significant adverse events, while 5-fluorouracil had an 88% response rate and 20% relapse rate.
Impact:
- Interferon alpha 2b emerges as a favorable option due to its high efficacy and favorable safety profile.
- Mitomycin C is effective but limited by adverse events, and 5-fluorouracil is considered a secondary treatment option.